非糖尿病急性缺血性卒中患者的β细胞功能与临床结局
前瞻性研究纳入3590例非糖尿病急性缺血性卒中患者,随访3个月,评估β细胞功能(HOMA-β)与临床结局的关系。结果显示HOMA-β水平越低,功能预后不良和神经功能恶化的风险越高,且独立于胰岛素抵抗;卒中复发无此关联。
要点
- 非糖尿病急性缺血性卒中患者HOMA-β降低与3个月功能预后不良独立相关。
- HOMA-β降低与住院期间神经功能恶化独立相关,风险比更高。
- HOMA-β与卒中复发无显著关联。
核心结论
- 非糖尿病急性缺血性卒中患者β细胞功能障碍与短期功能预后不良和神经功能恶化独立相关,且不依赖于胰岛素抵抗。
研究设计与样本
- 前瞻性研究纳入3590例非糖尿病急性缺血性卒中患者(平均年龄71岁),随访3个月。
- β细胞功能采用稳态模型评估β细胞功能(HOMA-β)评估。
- 结局包括3个月功能预后不良(改良Rankin量表评分3-6)、卒中复发和出院时神经功能恶化(NIHSS评分增加≥2分)。
- 采用logistic回归分析HOMA-β五分位水平与临床结局的关联。
主要发现
- 年龄和性别调整后,功能预后不良和神经功能恶化的比值比随HOMA-β水平降低而显著增加(趋势P值分别<0.001和0.001)。
- 进一步调整胰岛素抵抗后关联更显著,再调整BMI、血脂异常、高血压、eGFR、卒中亚型、入院NIHSS评分和再灌注治疗后基本不变。
- HOMA-β第一分位 vs 第五分位的比值比(95%CI):功能预后不良为3.30(2.15–5.08),神经功能恶化为10.69(4.99–22.90)。
- HOMA-β与卒中复发无显著关联。
- 分层分析显示,低HOMA-β和高HOMA-胰岛素抵抗水平均独立与功能预后不良和神经功能恶化风险增加相关。
关键数值与推荐
- 功能预后不良定义为改良Rankin量表评分3-6分。
- 神经功能恶化定义为出院时NIHSS评分较基线增加≥2分。
- HOMA-β第一分位 vs 第五分位功能预后不良OR=3.30(95%CI 2.15–5.08)。
- HOMA-β第一分位 vs 第五分位神经功能恶化OR=10.69(95%CI 4.99–22.90)。
临床怎么用
- 对非糖尿病急性缺血性卒中患者,可考虑评估β细胞功能(HOMA-β)以辅助识别短期预后不良高危人群。
- 低HOMA-β提示功能预后不良和神经功能恶化风险增加,需加强监测和干预。
- β细胞功能与卒中复发无关,复发预防策略应针对其他危险因素。
局限性
- 研究人群为非糖尿病急性缺血性卒中患者,结论不能外推至糖尿病患者。
- HOMA-β为间接评估指标,可能受其他因素影响。
- 随访时间仅3个月,长期结局未知。
- 观察性研究不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Little is known about how β-cell dysfunction affects clinical outcome after ischemic stroke. We examined whether β-cell function is associated with clinical outcome after acute ischemic stroke and if so, whether insulin resistance influences this association in a prospective study of patients with acute stroke. METHODS: A total of 3590 nondiabetic patients with acute ischemic stroke (mean age, 71 years) were followed up for 3 months. β-Cell function was assessed using the homeostasis model assessment for β-cell function (HOMA-β). Study outcomes were poor functional outcome (modified Rankin Scale score, 3–6) and stroke recurrence at 3 months after stroke onset and neurological deterioration (≥2-point increase in the National Institutes of Health Stroke Scale score) at discharge. Logistic regression analysis was used to evaluate the association between quintile levels of serum HOMA-β and clinical outcomes. RESULTS: The age- and sex-adjusted odds ratios for poor functional outcome and neurological deterioration increased significantly with decreasing HOMA-β levels (P for trend, <0.001 and 0.001, respectively). These associations became more prominent after adjustment for HOMA-insulin resistance and were substantially unchanged even after further adjustment for other confounders, namely, body mass index, dyslipidemia, hypertension, estimated glomerular filtration rate, stroke subtype, National Institutes of Health Stroke Scale score on admission, and reperfusion therapy (odds ratio [95% CI] for the first versus fifth quintile of HOMA-β, 3.30 [2.15–5.08] for poor functional outcome and 10.69 [4.99–22.90] for neurological deterioration). Such associations were not observed for stroke recurrence. In stratified analysis for the combination of HOMA-β and HOMA-insulin resistance levels, lower HOMA-β and higher HOMA-insulin resistance levels were independently associated with increased risks of poor functional outcome and neurological deterioration. CONCLUSIONS: Our findings suggest that β-cell dysfunction is significantly associated with poor short-term clinical outcome independently of insulin resistance in nondiabetic patients with acute ischemic stroke.
引用
- Kiyohara T, Matsuo R, Hata J, et al. β-Cell Function and Clinical Outcome in Nondiabetic Patients With Acute Ischemic Stroke. Stroke. 2021. PMID: 33985365. doi:10.1161/STROKEAHA.120.031392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。